Shuji Hiramoto
Mitsubishi
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shuji Hiramoto.
European Journal of Cancer | 2015
Mika Baba; Isseki Maeda; Tatsuya Morita; Satoshi Inoue; Masayuki Ikenaga; Yoshihisa Matsumoto; Ryuichi Sekine; Takashi Yamaguchi; Takeshi Hirohashi; Tsukasa Tajima; Ryohei Tatara; Hiroaki Watanabe; Hiroyuki Otani; Chizuko Takigawa; Yoshinobu Matsuda; Hiroka Nagaoka; Masanori Mori; Yo Tei; Shuji Hiramoto; Akihiko Suga; Hiroya Kinoshita
PURPOSE The aim of this study was to investigate the feasibility and accuracy of the Palliative Prognostic Score (PaP score), Delirium-Palliative Prognostic Score (D-PaP score), Palliative Prognostic Index (PPI) and modified Prognosis in Palliative Care Study predictor model (PiPS model). PATIENTS AND METHODS This multicentre prospective cohort study involved 58 palliative care services, including 19 hospital palliative care teams, 16 palliative care units and 23 home palliative care services, in Japan from September 2012 to April 2014. Analyses were performed involving four patient groups: those treated by palliative care teams, those in palliative care units, those at home and those receiving chemotherapy. RESULTS We recruited 2426 participants, and 2361 patients were finally analysed. Risk groups based on these instruments successfully identified patients with different survival profiles in all groups. The feasibility of PPI and modified PiPS-A was more than 90% in all groups, followed by PaP and D-PaP scores; modified PiPS-B had the lowest feasibility. The accuracy of prognostic scores was ⩾69% in all groups and the difference was within 13%, while c-statistics were significantly lower with the PPI than PaP and D-PaP scores. CONCLUSION The PaP score, D-PaP score, PPI and modified PiPS model provided distinct survival groups for patients in the three palliative care settings and those receiving chemotherapy. The PPI seems to be suitable for routine clinical use for situations where rough estimates of prognosis are sufficient and/or patients do not want invasive procedure. If clinicians can address more items, the modified PiPS-A would be a non-invasive alternative. In cases where blood samples are available or those requiring more accurate prediction, the PaP and D-PaP scores and modified PiPS-B would be more appropriate.
World Journal of Gastrointestinal Surgery | 2013
Tomohide Hori; Noriyuki Okada; Masaya Nakauchi; Shuji Hiramoto; Ayako Kikuchi-Mizota; Masahisa Kyogoku; Fumitaka Oike; Hidemitsu Sugimoto; Junya Tanaka; Yoshiki Morikami; Kaori Shigemoto; Toyotsugu Ota; Masanobu Kaneko; Masato Nakatsuji; Shunji Okae; Takahiro Tanaka; Daigo Gunji; Akira Yoshioka
Sister Mary Josephs nodule (SMJN) is a rare umbilical nodule that develops secondary to metastatic cancer. Primary malignancies are located in the abdomen or pelvis. Patients with SMJN have a poor prognosis. An 83-year-old woman presented to our hospital with a 1-month history of a rapidly enlarging umbilical mass. Endoscopic findings revealed advanced transverse colon cancer. computer tomography and fluorodeoxyglucose-positron emission tomography revealed tumors of the transverse colon, umbilicus, right inguinal lymph nodes, and left lung. The feeding arteries and drainage veins for the SMJN were the inferior epigastric vessels. Imaging findings of the left lung tumor allowed for identification of the primary lung cancer, and a diagnosis of advanced transverse colon cancer with SMJN and primary lung cancer was made. The patient underwent local resection of the SMNJ and subsequent single-site laparoscopic surgery involving right hemicolectomy and paracolic lymph node dissection. Intra-abdominal dissemination to the mesocolon was confirmed during surgery. Histopathologically, the transverse colon cancer was confirmed to be moderately differentiated tubular adenocarcinoma. We suspect that SMJN may occur via a hematogenous pathway. Although chemotherapy for colon cancer and thoracoscopic surgery for the primary lung cancer were scheduled, the patient and her family desired home hospice. Seven months after surgery, she died of rapidly growing lung cancer.
Palliative Medicine | 2017
Jun Hamano; Yasuharu Tokuda; Shohei Kawagoe; Takuya Shinjo; Hiroto Shirayama; Taketoshi Ozawa; Hideki Shishido; Sen Otomo; Jun Nagayama; Mika Baba; Yo Tei; Shuji Hiramoto; Akihiko Suga; Takayuki Hisanaga; Tatsuhiko Ishihara; Tomoyuki Iwashita; Keisuke Kaneishi; Toshiyuki Kuriyama; Takashi Maeda; Tatsuya Morita
Background: Changes in activities of daily living in cancer patients may predict their survival. The Palliative Prognostic Index is a useful tool to evaluate cancer patients, and adding an item about activities of daily living changes might improve its predictive value. Aim: To clarify whether adding an item about activities of daily living changes improves the accuracy of Palliative Prognostic Index. Design: Multicenter prospective cohort study. Setting: A total of 58 palliative care services in Japan. Participants: Patients aged >20 years diagnosed with locally extensive or metastatic cancer (including hematological neoplasms) who had been admitted to palliative care units, were receiving care by hospital-based palliative care teams, or were receiving home-based palliative care. Palliative care physicians recorded clinical variables at the first assessment and followed up patients 6 months later. Results: A total of 2425 subjects were recruited and 2343 of these had analyzable data. The C-statistic of the original Palliative Prognostic Index was 0.801, and those of modified Palliative Prognostic Indices ranged from 0.793 to 0.805 at 3 weeks. For 6-week survival predictions, the C-statistic of the original Palliative Prognostic Index was 0.802, and those of modified Palliative Prognostic Indices ranged from 0.791 to 0.799. The weighted kappa of the original Palliative Prognostic Index was 0.510, and those of modified Palliative Prognostic Indices ranged from 0.484 to 0.508. Conclusion: Adding items about activities of daily living changes to the Palliative Prognostic Index did not improve prognostic value in advanced cancer patients.
PLOS ONE | 2017
Yu Uneno; Kei Taneishi; Masashi Kanai; Kazuya Okamoto; Yosuke Yamamoto; Akira Yoshioka; Shuji Hiramoto; Akira Nozaki; Yoshitaka Nishikawa; Daisuke Yamaguchi; Teruko Tomono; Masahiko Nakatsui; Mika Baba; Tatsuya Morita; Shigemi Matsumoto; Tomohiro Kuroda; Yasushi Okuno; Manabu Muto
Background We aimed to develop an adaptable prognosis prediction model that could be applied at any time point during the treatment course for patients with cancer receiving chemotherapy, by applying time-series real-world big data. Methods Between April 2004 and September 2014, 4,997 patients with cancer who had received systemic chemotherapy were registered in a prospective cohort database at the Kyoto University Hospital. Of these, 2,693 patients with a death record were eligible for inclusion and divided into training (n = 1,341) and test (n = 1,352) cohorts. In total, 3,471,521 laboratory data at 115,738 time points, representing 40 laboratory items [e.g., white blood cell counts and albumin (Alb) levels] that were monitored for 1 year before the death event were applied for constructing prognosis prediction models. All possible prediction models comprising three different items from 40 laboratory items (40C3 = 9,880) were generated in the training cohort, and the model selection was performed in the test cohort. The fitness of the selected models was externally validated in the validation cohort from three independent settings. Results A prognosis prediction model utilizing Alb, lactate dehydrogenase, and neutrophils was selected based on a strong ability to predict death events within 1–6 months and a set of six prediction models corresponding to 1,2, 3, 4, 5, and 6 months was developed. The area under the curve (AUC) ranged from 0.852 for the 1 month model to 0.713 for the 6 month model. External validation supported the performance of these models. Conclusion By applying time-series real-world big data, we successfully developed a set of six adaptable prognosis prediction models for patients with cancer receiving chemotherapy.
Journal of Clinical Oncology | 2015
Shuji Hiramoto; Ken Kato; Hirokazu Shoji; Natsuko Okita; Atsuo Takashima; Yoshitaka Honma; Satoru Iwasa; Tetsuya Hamaguchi; Yasuhide Yamada; Yasuhiro Shimada
204 Background: Patients with metastatic or recurrent esophageal squamous cell carcinoma (ESCC) have a poor prognosis. For decades, 5-fluorouracil /Cisplatin (FP) have been mostly used for these patients as first line chemotherapy. But there were few reports which reveal the reality containing the efficacy of FP regimen for ESCC. We conduct this retrospective study to reveal the efficacy and prognostic factors of the patients treated with FP as first line chemotherapy for ESCC. Methods: Patients with metastatic or recurrent ESCC after esophagectomy were enrolled. FP comprised of CDDP at a dose of 80mg/m2 on day1, and 5-FU at a dose of 800mg/m2given by continuous on days 1-5 every 4 weeks. Cox-proportional hazard model was used for multivariate analysis to evaluate prognostic factors. Results: Between April 2001 and March 2012 in the National Cancer Center Hospital, data of 187 patients were collected by medical records. Characteristics of 187 patients were as follows; the median age (range) 62 (34-84); (m...
Journal of Pain and Symptom Management | 2016
Naoki Matsuo; Tatsuya Morita; Yoshinobu Matsuda; Kenichiro Okamoto; Yoshihisa Matsumoto; Keisuke Kaneishi; Takuya Odagiri; Hiroki Sakurai; Hideki Katayama; Ichiro Mori; Hirohide Yamada; Hiroaki Watanabe; Taro Yokoyama; Takashi Yamaguchi; Tomohiro Nishi; Akemi Shirado; Shuji Hiramoto; Toshio Watanabe; Hiroyuki Kohara; Satofumi Shimoyama; Etsuko Aruga; Mika Baba; Koki Sumita; Satoru Iwase
Palliative Care Research | 2015
Shuji Hiramoto; Ayako Kikuchi; Akira Yoshioka; Yuka Otsu; Yasushi Kohigashi; Yoko Goto; Yurie Tsutsumi; Masahiro Hiraoka; Koji Ono
International Journal of Clinical Oncology | 2018
Shuji Hiramoto; Ken Kato; Hirokazu Shoji; Natsuko Okita; Atsuo Takashima; Yoshitaka Honma; Satoru Iwasa; Tetsuya Hamaguchi; Yasuhide Yamada; Yasuhiro Shimada; Narikazu Boku
Supportive Care in Cancer | 2017
Naoki Matsuo; Tatsuya Morita; Yoshinobu Matsuda; Kenichiro Okamoto; Yoshihisa Matsumoto; Keisuke Kaneishi; Takuya Odagiri; Hiroki Sakurai; Hideki Katayama; Ichiro Mori; Hirohide Yamada; Hiroaki Watanabe; Taro Yokoyama; Takashi Yamaguchi; Tomohiro Nishi; Akemi Shirado; Shuji Hiramoto; Toshio Watanabe; Hiroyuki Kohara; Satofumi Shimoyama; Etsuko Aruga; Mika Baba; Koki Sumita; Satoru Iwase
Supportive Care in Cancer | 2017
Masanori Mori; Akemi Shirado; Tatsuya Morita; Kenichiro Okamoto; Yoshinobu Matsuda; Yoshihisa Matsumoto; Hirohide Yamada; Hiroki Sakurai; Etsuko Aruga; Keisuke Kaneishi; Hiroaki Watanabe; Takashi Yamaguchi; Takuya Odagiri; Shuji Hiramoto; Hiroyuki Kohara; Naoki Matsuo; Hideki Katayama; Tomohiro Nishi; Takashi Matsui; Satoru Iwase